Published Online: Saturday, December 1, 2007

New labeling on the the erectile dysfunction drugs Cialis (tadalafil tablets), Levitra (vardenafil HCl), and Viagra (sildenafil citrate) will warn men of possible hearing loss resulting from these products.

The new FDA warnings were developed after what agency officials described as a ?very small number? of patients who experienced sudden loss of hearing after taking the drugs.

FDA said it plans to require the same label warnings for Revatio (sildenafil citrate), for pulmonary arterial hypertension. The FDA is currently working with the sponsor to revise the label for Revatio.

Latest Articles
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Latest Issues